Skip to content

Author

Mansuor A. Alanazi

8 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Rising burden of chronic kidney disease attributable to high fasting plasma glucose in the Middle East and North Africa, 1990-2023

Introduction: Chronic kidney disease (CKD) attributable to high fasting plasma glucose (HFPG) is rising globally, particularly in regions with rapidly increasing dysglycemia such as the Middle East and North Africa (MENA). We assessed long-term trends in HFPG-attributable CKD burden across 21 MENA countries from 1990 t...

Aya Abdulrahman Ajeel, Abdullah I. Alzimam, Sharifah Alraythi et al. · 0 citations
Open access Nov 2026

Inflammatory biomarker profiles and their associations with Nordic dietary habits and metabolic outcomes in adults affected by MAFLD

Metabolic dysfunction-associated fatty liver disease (MAFLD) is commonly accompanied by chronic low-grade inflammation. The Aggregate Index of Systemic Inflammation (AISI) is an accessible inflammatory marker, while the Healthy Nordic diet may have favorable metabolic effects. This study investigated relationships amon...

Amr A. El-Sehrawy, Ismail Kandil, G. Elmazny et al. · 0 citations
Review Open access Oct 2026

SGLT2 Inhibitors Reduce Heart Failure Hospitalization, Cardiovascular Death and Kidney Outcomes in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

These findings support proactive, guideline-concordant initiation of evidence-based SGLT2i agents by endocrinologists, cardiologists and primary care providers as foundational therapy in type 2 diabetes mellitus.

Ahmed Elbataa, A. Mansour, Ahmed Elazab et al. · 0 citations
Open access Oct 2026

Neutrophil-to-lymphocyte ratio (NLR) in relation to metabolic profile and dietary antioxidant quality in adults with non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) is a common metabolic condition characterized by hepatic steatosis and chronic low-grade inflammation, with oxidative stress playing a pivotal role in its progression. The neutrophil-to-lymphocyte ratio (NLR) has been proposed as an accessible marker reflecting systemic inflamm...

Amr A. El-Sehrawy, Ahmed M. Salah, Ismail Kandil et al. · 0 citations
Open access Sep 2026

Association of the cardiometabolic index with hepatic enzymes and metabolic profiles among adults with overweight and obesity

Growing evidence suggests that composite metabolic indices may offer valuable insights into obesity-related complications. The Cardiometabolic Index (CMI), a surrogate marker of adverse lipid profiles and central adiposity, has emerged as a promising indicator of cardiometabolic risk. Nevertheless, its association with...

Amr A. El-Sehrawy, Ismail Kandil, M. Maashi et al. · 0 citations
Open access Sep 2026

Dietary index for gut microbiota (DIGM) and cardiometabolic, inflammatory, and gut–brain-related biomarkers in adults with obesity: a cross-sectional study

Background The gut microbiota plays an important role in metabolic homeostasis and systemic inflammation, and dietary habits are major determinants of its composition and function. This study investigated the association between adherence to the Dietary Index for Gut Microbiota (DIGM) and cardiometabolic, inflammatory,...

Amr A. El-Sehrawy, Ismail Kandil, Safa Labib et al. · 0 citations
#gene editing Review Sep 2026

Engineering Immune-Protective Stem Cell-Derived β-Cell Grafts for Type 1 Diabetes: Encapsulation Technologies and the Emerging Graft Ecosystem.

BACKGROUND Stem cell-derived β-cell replacement has emerged as a promising strategy for the treatment of type 1 diabetes (T1D), potentially addressing the limitations of exogenous insulin therapy and donor-dependent islet transplantation. However, despite substantial progress in stem cell differentiation and transplant...

Mansuor A. Alanazi · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.